ODT Key Statistics, Chart & Performance
The current stock price of ODT is 1.12 null. In the past month the price decreased by -21.13%. In the past year, price decreased by -94.4%.
ODT Technical Analysis
ODT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ODT. ODT may be in some trouble as it scores bad on both profitability and health.
ODT Financial Highlights
Over the last trailing twelve months ODT reported a non-GAAP Earnings per Share(EPS) of -2.68. The EPS increased by 31.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.5% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ODT Forecast & Estimates
9 analysts have analysed ODT and the average price target is 4.08 null. This implies a price increase of 264.29% is expected in the next year compared to the current price of 1.12.
ODT Ownership
ODT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.22 | 981.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.07 | 526.82B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.12B | ||
| PFE | PFIZER INC | 8.02 | 145.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.42 | 112.50B | ||
| ZTS | ZOETIS INC | 19.66 | 54.93B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.83B | ||
| VTRS | VIATRIS INC | 5.52 | 14.81B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.55 | 12.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.94B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 5.38B |
Related stock screener links
About ODT
Company Profile
Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. The company is headquartered in New York City, New York and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company is focused on the development of tesetaxel, a novel chemotherapy agent.
Company Info
Odonate Therapeutics Inc
3 East 28Th Street, 10Th Floor
New York City NEW YORK 10016 US
CEO: Kevin Tang
Employees: 137
Phone: 13322060935.0
Odonate Therapeutics Inc / ODT FAQ
Can you describe the business of Odonate Therapeutics Inc?
Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. The company is headquartered in New York City, New York and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company is focused on the development of tesetaxel, a novel chemotherapy agent.
What is the current price of ODT stock?
The current stock price of ODT is 1.12 null. The price decreased by -4.27% in the last trading session.
Does ODT stock pay dividends?
ODT does not pay a dividend.
How is the ChartMill rating for Odonate Therapeutics Inc?
ODT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does Odonate Therapeutics Inc belong to?
Odonate Therapeutics Inc (ODT) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for ODT stock?
Odonate Therapeutics Inc (ODT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.68).
What is the next earnings date for ODT stock?
Odonate Therapeutics Inc (ODT) will report earnings on 2022-03-01, before the market open.